CTOs on the Move

Uroplasty

www.uroplasty.com

 
Uroplasty is a global medical company committed to offering transformative treatment options through specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Uroplasty’s products include the Urgent® PC Neuromodulation System, a non-drug, non-surgical office-based treatment for Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Urgent PC is an FDA-cleared system that delivers PTNS (Percutaneous Tibial Nerve Stimulation) and is also indicated for the treatment of fecal incontinence outside the US market. Uroplasty also offers Macroplastique®, an injectable urethral bulking agent ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Reemo Health

Reemo Health is a Remote Mobile Health platform. Reemo Smartwatch provides live personal health data and connectivity with family, caregivers, care facilities and healthcare contacts to improve health and wellness outcomes.

Austin Weston Center

Austin Weston Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Austin Weston Center is based in Reston, VA. You can find more information on Austin Weston Center at www.austin-weston.com

Mid Dakota Clinic

Mid Dakota Clinic - The doctors you know and trust. A full-service clinic, offering services for diagnosis and treatment of illness and injury. We help our patients make wise choices for a healthy lifestyle.

Crowne Management

Crowne Management is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Monroeville, AL. To find more information about Crowne Management, please visit www.crownemanagement.com

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.